Articles
Page 6 of 19
-
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P236
-
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P234 -
Prevalence and risk factors for chronic obstructive lung disease in HIV-infected patients in the HAART era
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P232 -
Novel monitoring technique to minimise the risk for patients participating in pilot studies of investigational compounds
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P228 -
Do interleukin-28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P205 -
Correlates of hepatic stiffness by FibroScan© in a multicentric Italian cohort of HIV-infected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P203 -
High prevalence of genotype G in HIV co-infected patients compared with HBV monoinfected patients in México
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P201 -
Sudden unexplained death in a patient with HIV and MDR-TB
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P198 -
Therapy of the patients with HIV/TB infection and dynamics of level 'naïve' CD4-lymphocytes
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P196 -
Five-year outcomes of HAART at a non-governmental treatment center in Lima, Peru
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P173 -
Newly diagnosed HIV patients in Lima, Peru: a comparison of individuals diagnosed through an intervention program versus self-referred individuals
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P171 -
A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P169 -
Older HIV-infected individuals present late and have a higher mortality: a UK clinic cohort study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P167 -
A method to estimate the number of people in a country or region with HIV who are undiagnosed and in need of ART
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P165 -
Amniocentesis is a low-risk procedure in HIV-treated pregnant women
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P163 -
Use of antiretroviral therapy during pregnancy among HIV-infected women attending an urban care centre
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P161 -
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P159 -
Salvage therapy with raltegravir in a 3-month-old infant
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P157 -
Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P134 -
Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P132 -
Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P130 -
Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P128 -
Analysis of transmitted drug resistance, resistance mutations and future antiretroviral efficacy in HIV-1 subtype F infected-patients prior to therapy
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P126 -
Identifying causes of loss to follow up in newly diagnosed HIV-infected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P124 -
Quantitative ultrasound (QUS) in HIV-infected patients: a reliable and low-cost technique for bone health assessment
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P98 -
Adiponectin and leptin levels in HIV-infected patients with lipodystrophy in Southern India
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P75 -
Lipodystrophy and metabolic syndrome in Romanian HIV-infected adults
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P71 -
Higher red blood cell distribution width is associated with a worse virologic and clinical situation in HIV-infected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P69 -
Prevalence of cardiovascular risk factors in Spanish HIV-1-infected male inmates
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P67 -
Incidence of ischemic cardiovascular events in the maraviroc clinical development program
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P65 -
Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of treatment: results from the ROCKET 1 study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P42 -
Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P40 -
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P36 -
Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P34 -
0314. Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O32 -
Integrase inhibitor-based treatment in clinical practice
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P32 -
0312. Host genetics of HCV disease — IL28B
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O30 -
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P30 -
0234. Mitochondrial ageing and antiretroviral therapy exposure
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O28 -
Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P28 -
0232. HIV therapy in an ageing population — the challenge of polypharmacy
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O26 -
Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P26 -
0223. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O24 -
0221. The clinical development of NRTIs — cautionary tales
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O22 -
O212. Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O18 -
O123. Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O9 -
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P7 -
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P5 -
O115. Low-level residual viremia and risk of virological failure
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O5 -
Health-related quality of life and fatigue in HIV-1 infected patients diagnosed during primary versus chronic infection
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P1